General Information of Drug Combination (ID: DC2A9FF)

Drug Combination Name
Emtricitabine Tenofovir alafenamide
Indication
Disease Entry Status REF
Human immunodeficiency virus-1 infection Phase 1 [1]
Component Drugs Emtricitabine   DMBMUWZ Tenofovir alafenamide   DMTQF4A
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Emtricitabine
Disease Entry ICD 11 Status REF
Hepatitis virus infection 1E50-1E51 Approved [2]
Human immunodeficiency virus infection 1C62 Approved [2]
Hepatitis B virus infection 1E51.0 Phase 3 [3]
Emtricitabine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [2]
------------------------------------------------------------------------------------
Emtricitabine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [5]
------------------------------------------------------------------------------------
Emtricitabine Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Decreases Expression [6]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [7]
Deoxycytidine kinase (DCK) OTW8HLZC DCK_HUMAN Affects Binding [8]
------------------------------------------------------------------------------------
Indication(s) of Tenofovir alafenamide
Disease Entry ICD 11 Status REF
HIV infectious disease N.A. Approved [4]
Tenofovir alafenamide Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Tenofovir alafenamide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [10]
Cathepsin A (CTSA) DE14JZK PPGB_HUMAN Metabolism [11]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
HIV DCZ4OHF N. A. Phase 3 [12]
Human immunodeficiency virus-1 infection DCJIOQC N. A. Phase 1 [1]
HIV DCA6JSD N. A. Phase 1 [13]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3 Clinical pipeline report, company report or official report of Gilead (2011).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017 Jan;47(1):77-85.
6 Chronic Nucleoside Reverse Transcriptase Inhibitors Disrupt Mitochondrial Homeostasis and Promote Premature Endothelial Senescence. Toxicol Sci. 2019 Dec 1;172(2):445-456. doi: 10.1093/toxsci/kfz203.
7 Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
8 Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides. J Med Chem. 2007 Jun 28;50(13):3004-14. doi: 10.1021/jm0700215. Epub 2007 May 27.
9 Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472.
10 FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
11 Bictegravir/Emtricitabine/Tenofovir Alafenamide: a review in HIV-1 infection. Drugs. 2018 Nov;78(17):1817-1828.
12 ClinicalTrials.gov (NCT05979311) A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
13 ClinicalTrials.gov (NCT02904369) PK and PD Study of Oral F/TAF for HIV Prevention